Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Active not recruiting 9Recruiting 4Completed 4Not yet recruiting 2Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1ALK Positive Non-small Cell Lung Cancer 1

Interventions

Specimen Handling 81Bevacizumab 66Drug Therapy 64Cisplatin 63Magnetic Resonance Spectroscopy 61Carboplatin 60Gemcitabine 57Radiotherapy 55Cyclophosphamide 55pembrolizumab 52Oxaliplatin 50Capecitabine 50toripalimab 42Paclitaxel 41tislelizumab 40Standard of Care 40Biopsy 38fludarabine 36Fluorouracil 36venetoclax 32Blood Specimen Collection 31Irinotecan 30Injections 30Immune Checkpoint Inhibitors 30anlotinib 29Nivolumab 29Docetaxel 29Surgical Procedures, Operative 28Leucovorin 27Dexamethasone 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × lorlatinib × 1 year × Clear all
NCT07617337 2026-06-01

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

Chugai Pharmaceutical

Phase 1 Not yet recruiting
102 enrolled
Thoracic

ALK Positive Non-small Cell Lung Cancer

NCT07083687 2025-07-24

Lorlatinib in ROS1+ NSCLC With Brain Metastasis

Hunan Cancer Hospital

Phase 2 Not yet recruiting
21 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡